Forty-Eight Week Efficacy, Safety of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria and Suboptimal Response to Prior Eculizumab Treatment
Injection Site Reactions at Week 48 in the Phase 3 Trial of Pegcetacoplan Versus Eculizumab for Individuals with Paroxysmal Nocturnal Hemoglobinuria
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.
You are entering a website that is technical in nature and was created for scientific exchange with U.S. Healthcare Professionals. The content on this website may include scientific information about investigational compounds or indications that are not approved. Apellis does not support, endorse or recommend the unapproved use of any compound, including those discussed on this website.
Are you a U.S. Healthcare Professional licensed to practice in the United States?
If you are not a U.S. Healthcare Professional, you will be redirected to www.apellis.com